Literature DB >> 9264274

A hot spot for p53 mutation in transitional cell carcinoma of the bladder: clues to the etiology of bladder cancer.

X Xu1, M J Stower, I N Reid, R C Garner, P A Burns.   

Abstract

Twenty-eight transitional cell carcinomas of the bladder, grade 2 or 3, were analyzed for the presence of p53 mutations. Thirteen tumors were found to contain 14 mutations. These were all base substitution mutations, of which nine were GC-->AT transitions (three at CpG sites). The remaining five mutations were transversions (three GC-->CG, one GC-->TA, and one AT-->TA). Four of the mutations were found at codon 280. A comparison with other studies of bladder tumors reveals that a region encompassing codons 280 and 285 represents a hot spot for p53 mutation in bladder cancer. The 280/285 hot spot lies within two purine-rich sequences that may provide some clues to the identity of potential bladder carcinogens. A comparison of mutations from bladder tumors of smokers and nonsmokers reveals no significant differences.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9264274

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  7 in total

1.  MRE11 expression is predictive of cause-specific survival following radical radiotherapy for muscle-invasive bladder cancer.

Authors:  Ananya Choudhury; Louisa D Nelson; Mark T W Teo; Sameer Chilka; Selina Bhattarai; Colin F Johnston; Faye Elliott; Johanna Lowery; Claire F Taylor; Michael Churchman; Johanne Bentley; Margaret A Knowles; Patricia Harnden; Robert G Bristow; D Timothy Bishop; Anne E Kiltie
Journal:  Cancer Res       Date:  2010-09-15       Impact factor: 12.701

2.  Radiation induces p53-dependent cell apoptosis in bladder cancer cells with wild-type- p53 but not in p53-mutated bladder cancer cells.

Authors:  Nobuyuki Hinata; Toshiro Shirakawa; Zhujun Zhang; Akira Matsumoto; Masato Fujisawa; Hiroshi Okada; Sadao Kamidono; Akinobu Gotoh
Journal:  Urol Res       Date:  2003-09-04

3.  p53 mutations in urinary bladder cancer.

Authors:  P Berggren; G Steineck; J Adolfsson; J Hansson; O Jansson; P Larsson; B Sandstedt; H Wijkström; K Hemminki
Journal:  Br J Cancer       Date:  2001-06-01       Impact factor: 7.640

4.  Deletion/duplication mutation screening of TP53 gene in patients with transitional cell carcinoma of urinary bladder using multiplex ligation-dependent probe amplification.

Authors:  Mohammad Reza R Bazrafshani; Pouriaali A Nowshadi; Sadegh Shirian; Yahya Daneshbod; Fatemeh Nabipour; Maral Mokhtari; Fatemehsadat Hosseini; Somayeh Dehghan; Abolfazl Saeedzadeh; Ziba Mosayebi
Journal:  Cancer Med       Date:  2015-12-21       Impact factor: 4.452

5.  Expression of MDM2 mRNA, MDM2, P53 and P16 Proteins in Urothelial Lesions in the View of the WHO 4th Edition Guidelines as a Molecular Insight towards Personalized Medicine.

Authors:  Olfat Hammam; Mona Magdy; Mohamed Badawy; Khalid Al Osili; Amr El Kholy; Tarek El LeitHy
Journal:  Open Access Maced J Med Sci       Date:  2017-08-05

6.  p53 status in multiple human urothelial cancers: assessment for clonality by the yeast p53 functional assay in combination with p53 immunohistochemistry.

Authors:  S Yamamoto; M Tada; C C Lee; C Masuda; H Wanibuchi; R Yoshimura; S Wada; K Yamamoto; T Kishimoto; S Fukushima
Journal:  Jpn J Cancer Res       Date:  2000-02

7.  Characterization of circulating breast cancer cells with tumorigenic and metastatic capacity.

Authors:  Claudia Koch; Andra Kuske; Cathrin Brisken; Sabine Riethdorf; Catherine Alix-Panabières; Simon A Joosse; Gökhan Yigit; George Sflomos; Sonja Thaler; Daniel J Smit; Stefan Werner; Kerstin Borgmann; Sebastian Gärtner; Parinaz Mossahebi Mohammadi; Laura Battista; Laure Cayrefourcq; Janine Altmüller; Gabriela Salinas-Riester; Kaamini Raithatha; Arne Zibat; Yvonne Goy; Leonie Ott; Kai Bartkowiak; Tuan Zea Tan; Qing Zhou; Michael R Speicher; Volkmar Müller; Tobias M Gorges; Manfred Jücker; Jean-Paul Thiery; Klaus Pantel
Journal:  EMBO Mol Med       Date:  2020-07-15       Impact factor: 12.137

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.